259 related articles for article (PubMed ID: 28895119)
21. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
22. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
[TBL] [Abstract][Full Text] [Related]
23. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
[TBL] [Abstract][Full Text] [Related]
24. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
25. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
26. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
27. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter.
Shen H; Zhang Y; Ding H; Wang X; Chen L; Jiang H; Shen X
Cell Physiol Biochem; 2008; 22(1-4):1-14. PubMed ID: 18769028
[TBL] [Abstract][Full Text] [Related]
29. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
[TBL] [Abstract][Full Text] [Related]
30. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
31. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.
Xiong X; Wang X; Lu Y; Wang E; Zhang Z; Yang J; Zhang H; Li X
J Hepatol; 2014 Apr; 60(4):847-54. PubMed ID: 24333182
[TBL] [Abstract][Full Text] [Related]
32. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
33. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters.
Hoeke MO; Plass JR; Heegsma J; Geuken M; van Rijsbergen D; Baller JF; Kuipers F; Moshage H; Jansen PL; Faber KN
Hepatology; 2009 Jan; 49(1):151-9. PubMed ID: 19111018
[TBL] [Abstract][Full Text] [Related]
34. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Gai Z; Gui T; Hiller C; Kullak-Ublick GA
J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
[TBL] [Abstract][Full Text] [Related]
35. Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase.
Miyata M; Matsuda Y; Tsuchiya H; Kitada H; Akase T; Shimada M; Nagata K; Gonzalez FJ; Yamazoe Y
Drug Metab Pharmacokinet; 2006 Aug; 21(4):315-23. PubMed ID: 16946559
[TBL] [Abstract][Full Text] [Related]
36. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
37. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
[TBL] [Abstract][Full Text] [Related]
38. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
[TBL] [Abstract][Full Text] [Related]
39. Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice.
Li L; Liu H; Peng J; Wang Y; Zhang Y; Dong J; Liu X; Guo D; Jiang Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):880-5. PubMed ID: 24211198
[TBL] [Abstract][Full Text] [Related]
40. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β.
Noh K; Kim YM; Kim YW; Kim SG
Drug Metab Dispos; 2011 Aug; 39(8):1451-9. PubMed ID: 21596890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
